# The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation

Study · id `cardio:ct-nct07314047` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07314047](<https://clinicaltrials.gov/study/NCT07314047>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07314047

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 116 participants.

## Technical summary

Registry record NCT07314047. Randomized; no masking; primary purpose treatment. Start 2024-05-28 (actual); primary completion 2025-05-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 116 participants (planned count; ClinicalTrials.gov record NCT07314047, source copy `cardio:ctgov-nct07314047-2026-01-02`, retrieved 2026-11-18)
- Started: 2024-05-28 (actual) (ClinicalTrials.gov record NCT07314047, source copy `cardio:ctgov-nct07314047-2026-01-02`, retrieved 2026-11-18)
- Primary completion: 2025-05-28 (actual) (ClinicalTrials.gov record NCT07314047, source copy `cardio:ctgov-nct07314047-2026-01-02`, retrieved 2026-11-18)
- Completion: 2026-05-28 (anticipated) (ClinicalTrials.gov record NCT07314047, source copy `cardio:ctgov-nct07314047-2026-01-02`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07314047, source copy `cardio:ctgov-nct07314047-2026-01-02`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07314047-2026-01-02`, retrieved 2026-11-18)

## The registry's words

- Brief title: The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation
- Acronym: PARTNER
- Condition: Brain Arteriovenous Malformation
- Condition: Arteriovenous Fistula
- Intervention (Device): liquid embolic agent
- Lead sponsor: MicroPort NeuroTech Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arteriovenous malformation (AVM) (`cardio:arteriovenous-malformation`)
- Registry lists this organization as the lead sponsor: MicroPort NeuroTech Co., Ltd. (`cardio:org-microport-neurotech-co-ltd`)

## Provenance

Content hash: 7696ffa28d8afa3996e8379a5b19440c1707c81f01e69084a5f1caa68b03d73a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
